{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:12:01Z","timestamp":1764079921883,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10157-023-02385-3","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T11:02:17Z","timestamp":1690455737000},"page":"919-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin II receptor blockers and bone fracture in chronic kidney disease patients: the Fukuoka kidney disease Registry Study"],"prefix":"10.1007","volume":"27","author":[{"given":"Tomoya","family":"Shukuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tokumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-5615","authenticated-orcid":false,"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2385_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0158765.","journal-title":"PLoS ONE"},{"key":"2385_CR2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038\u201347.","journal-title":"JAMA"},{"key":"2385_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","volume":"13","author":"E Imai","year":"2009","unstructured":"Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"2385_CR4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/jbmr.2862","volume":"31","author":"SM Kim","year":"2016","unstructured":"Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res. 2016;31:1803\u20139.","journal-title":"J Bone Miner Res"},{"key":"2385_CR5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.ajkd.2020.02.450","volume":"76","author":"T Vilaca","year":"2020","unstructured":"Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E, et al. Risks of hip and nonvertebral fractures in patients with CKD G3a\u2013G5D: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76:521\u201332.","journal-title":"Am J Kidney Dis"},{"key":"2385_CR6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.ajkd.2007.08.019","volume":"51","author":"AC Dooley","year":"2008","unstructured":"Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis. 2008;51:38\u201344.","journal-title":"Am J Kidney Dis"},{"key":"2385_CR7","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1210\/jc.2010-0099","volume":"95","author":"H Kaji","year":"2010","unstructured":"Kaji H, Yamauchi M, Yamaguchi T, Shigematsu T, Sugimoto T. Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab. 2010;95:4635\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"2385_CR8","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-005-1903-7","volume":"16","author":"L Dukas","year":"2005","unstructured":"Dukas L, Schacht E, St\u00e4helin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml\/min is a risk factor for falls and fractures. Osteoporos Int. 2005;16:1683\u201390.","journal-title":"Osteoporos Int"},{"key":"2385_CR9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser L-A, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10:646\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2385_CR10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.1984.229","volume":"26","author":"RD Lindeman","year":"1984","unstructured":"Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861\u20138.","journal-title":"Kidney Int"},{"key":"2385_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ndt\/gfv369","volume":"31","author":"\u0141 Zdrojewski","year":"2016","unstructured":"Zdrojewski \u0141, Zdrojewski T, Rutkowski M, Bandosz P, Kr\u00f3l E, Wyrzykowski B, et al. Prevalence of chronic kidney disease in a representative sample of the Polish population: results of the NATPOL 2011 survey. Nephrol Dial Transplant. 2016;31:433\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2385_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00223-021-00851-2","volume":"109","author":"S Yamada","year":"2021","unstructured":"Yamada S, Tanaka S, Arase H, Hiyamuta H, Yoshizumi E, Tokumoto M, et al. Associations between surrogates of skeletal muscle mass and history of bone fracture in patients with chronic kidney disease: the Fukuoka kidney disease registry (FKR) study. Calcif Tissue Int. 2021;109:393\u2013404.","journal-title":"Calcif Tissue Int"},{"key":"2385_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10157-022-02289-8","volume":"27","author":"S Yamada","year":"2023","unstructured":"Yamada S, Tanaka S, Arase H, Hiyamuta H, Kitamura H, Tokumoto M, et al. Association between prevalence of laxative use and history of bone fractures and cardiovascular diseases in patients with chronic kidney disease: the Fukuoka Kidney disease Registry (FKR) study. Clin Exp Nephrol. 2023;27:151\u201360.","journal-title":"Clin Exp Nephrol"},{"key":"2385_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75\u201385.","journal-title":"Bone"},{"key":"2385_CR15","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1523-1755.2000.00394.x","volume":"58","author":"CO Stehman-Breen","year":"2000","unstructured":"Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200\u20135.","journal-title":"Kidney Int"},{"key":"2385_CR16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","volume":"47","author":"MD Danese","year":"2006","unstructured":"Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149\u201356.","journal-title":"Am J Kidney Dis"},{"key":"2385_CR17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"P Muntner","year":"2010","unstructured":"Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441\u201351.","journal-title":"Am J Kidney Dis"},{"key":"2385_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135:73.","journal-title":"Ann Intern Med"},{"key":"2385_CR19","first-page":"6257","volume":"2","author":"GFM Strippoli","year":"2006","unstructured":"Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;2:6257.","journal-title":"Cochrane Database Syst Rev"},{"key":"2385_CR20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10157-015-1195-y","volume":"20","author":"S Tanaka","year":"2016","unstructured":"Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, et al. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol. 2016;20:689\u201398.","journal-title":"Clin Exp Nephrol"},{"key":"2385_CR21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/ggi.12406","volume":"15","author":"M Aoki","year":"2015","unstructured":"Aoki M, Kawahata H, Sotobayashi D, Yu H, Moriguchi A, Nakagami H, et al. Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome: effect of an ARB on bone metabolism in the elderly. Geriatr Gerontol Int. 2015;15:1064\u201372.","journal-title":"Geriatr Gerontol Int"},{"key":"2385_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11657-017-0387-3","volume":"12","author":"N Rianon","year":"2017","unstructured":"Rianon N, Ambrose CG, Pervin H, Garcia M, Mama SK, Schwartz AV, et al. Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African\u2013American elderly men. Arch Osteoporos. 2017;12:94.","journal-title":"Arch Osteoporos"},{"key":"2385_CR23","first-page":"57","volume":"46","author":"T Kwok","year":"2017","unstructured":"Kwok T, Leung J, Barrett-Connor E. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men. Age Ageing. 2017;46:57\u201364.","journal-title":"Age Ageing"},{"key":"2385_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122691","author":"S Yamamoto","year":"2015","unstructured":"Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa M, et al. Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0122691.","journal-title":"PLoS ONE"},{"key":"2385_CR25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10157-016-1294-4","volume":"21","author":"S Tanaka","year":"2017","unstructured":"Tanaka S, Ninomiya T, Fujisaki K, Yoshida H, Nagata M, Masutani K, et al. The Fukuoka Kidney disease Registry (FKR) Study: design and methods. Clin Exp Nephrol. 2017;21:465\u201373.","journal-title":"Clin Exp Nephrol"},{"key":"2385_CR26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2385_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/JBMR.051003","volume":"21","author":"L Rejnmark","year":"2005","unstructured":"Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2005;21:163\u201370.","journal-title":"J Bone Miner Res"},{"key":"2385_CR28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archinte.168.7.735","volume":"168","author":"LS Lim","year":"2008","unstructured":"Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE, et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med. 2008;168:735\u201340.","journal-title":"Arch Intern Med"},{"key":"2385_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-115-1-1","volume":"115","author":"FE Heidrich","year":"1991","unstructured":"Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture. Ann Intern Med. 1991;115:1\u20136.","journal-title":"Ann Intern Med"},{"key":"2385_CR30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/bbrc.1996.5914","volume":"230","author":"Y Hiruma","year":"1997","unstructured":"Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun. 1997;230:176\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2385_CR31","doi-asserted-by":"crossref","first-page":"21100","DOI":"10.1074\/jbc.A807610200","volume":"284","author":"Y Izu","year":"2009","unstructured":"Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009;284:21100.","journal-title":"J Biol Chem"},{"key":"2385_CR32","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1096\/fj.07-098954","volume":"22","author":"H Shimizu","year":"2008","unstructured":"Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22:2465\u201375.","journal-title":"FASEB J"},{"key":"2385_CR33","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1359\/jbmr.2001.16.8.1496","volume":"16","author":"S Beavan","year":"2001","unstructured":"Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res. 2001;16:1496\u2013504.","journal-title":"J Bone Miner Res"},{"key":"2385_CR34","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.3390\/ijms12074206","volume":"12","author":"X-X Guan","year":"2011","unstructured":"Guan X-X, Zhou Y, Li J-Y. Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1\/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis. Int J Mol Sci. 2011;12:4206\u201313.","journal-title":"Int J Mol Sci"},{"key":"2385_CR35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jbmr.4159","volume":"36","author":"T Wakamatsu","year":"2021","unstructured":"Wakamatsu T, Iwasaki Y, Yamamoto S, Matsuo K, Goto S, Narita I, et al. Type I angiotensin II receptor blockade reduces uremia-induced deterioration of bone material properties. J Bone Miner Res. 2021;36:67\u201379.","journal-title":"J Bone Miner Res"},{"key":"2385_CR36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/01.HYP.37.2.541","volume":"37","author":"LO Lerman","year":"2001","unstructured":"Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541\u20136.","journal-title":"Hypertension"},{"key":"2385_CR37","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.0000039528.49161.E9","volume":"106","author":"P Minuz","year":"2002","unstructured":"Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002;106:2800\u20135.","journal-title":"Circulation"},{"key":"2385_CR38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.33549\/physiolres.934779","volume":"70","author":"M Ku\u017ema","year":"2021","unstructured":"Ku\u017ema M, Jackuliak P, Killinger Z, Payer J. Parathyroid hormone-related changes of bone structure. Physiol Res. 2021;70:S3-11.","journal-title":"Physiol Res"},{"key":"2385_CR39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/01.CIR.92.4.825","volume":"92","author":"M Azizi","year":"1995","unstructured":"Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, M\u00e9nard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825\u201334.","journal-title":"Circulation"},{"key":"2385_CR40","first-page":"131","volume":"20","author":"MC Nevitt","year":"2005","unstructured":"Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, et al. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res. 2005;20:131\u201340.","journal-title":"J Bone Miner Res"},{"key":"2385_CR41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2796.2006.01695.x","volume":"260","author":"M Wiens","year":"2006","unstructured":"Wiens M, Etminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med. 2006;260:350\u201362.","journal-title":"J Intern Med"},{"key":"2385_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jbmr.5650100115","volume":"10","author":"G Jones","year":"1995","unstructured":"Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res. 1995;10:106\u201311.","journal-title":"J Bone Miner Res"},{"key":"2385_CR43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00198-018-4486-9","volume":"29","author":"X Xiao","year":"2018","unstructured":"Xiao X, Xu Y, Wu Q. Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies. Osteoporos Int. 2018;29:1515\u201324.","journal-title":"Osteoporos Int"},{"key":"2385_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005185.pub2","author":"K Aung","year":"2011","unstructured":"Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD005185.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2385_CR45","first-page":"F546","volume":"253","author":"DH Ellison","year":"1987","unstructured":"Ellison DH, Vel\u00e1zquez H, Wright FS. Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol. 1987;253:F546\u201354.","journal-title":"Am J Physiol"},{"key":"2385_CR46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.CIR.23.2.200","volume":"23","author":"FC Reubi","year":"1961","unstructured":"Reubi FC, Cottier PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation. 1961;23:200\u201310.","journal-title":"Circulation"},{"key":"2385_CR47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9629(15)40678-0","volume":"319","author":"DC Brater","year":"2000","unstructured":"Brater DC. Pharmacology of diuretics. Am J Med Sci. 2000;319:38\u201350.","journal-title":"Am J Med Sci"},{"key":"2385_CR48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacc.2008.03.039","volume":"52","author":"LD Carbone","year":"2008","unstructured":"Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol. 2008;52:135\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2385_CR49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/HJH.0b013e32834f6b43","volume":"30","author":"M Boschmann","year":"2012","unstructured":"Boschmann M, Nussberger J, Engeli S, Danser AHJ, Yeh C-M, Prescott MF, et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens. 2012;30:561\u20136.","journal-title":"J Hypertens"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02385-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T22:54:32Z","timestamp":1702853672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02385-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02385-3","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"27 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number UMIN000007988) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}